TG Therapeutics TGTX 深 沪
已收盘 10-10 16:00:00 美东时间
33.76
-1.210
-3.46%
华盛通- 最 高35.005
- 今 开34.86
- 成交量 209.91万股
- 最 低 33.10
- 昨 收 34.97
- 总市值 53.68亿
- 52周最高 46.48
- 市盈率 静 231.55
- 换手率 1.32%
- 52周最低 22.61
- 委 比 -39.84%
- 总股本 1.59亿
- 历史最高 56.74
- 量 比 1.39
- 振 幅 5.45%
- 历史最低 0.9563
- 每 手 1
- 风险率 4.76%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅4347.41%！Ascendiant Capital上调PAVmed目标价至20美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持PAVmed"买入"评级，目标价从19美元升至20美元；Ascendiant Capital：维持Plus Therapeutics"买入"评级，目标价从20.5美元升至21美元
10-07 15:04
IHC Wainwright & Co. Assumes TG Therapeutics at Buy, Announces Price Target of $60
HC Wainwright & Co. analyst Emily Bodnar assumes TG Therapeutics (NASDAQ:TGTX) with a Buy rating and announces Price Target of $60.
10-06 18:47
New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment
TG Therapeutics announced updated data on BRIUMVI for relapsing multiple sclerosis (RMS) at the 2025 ECTRIMS meeting. The six-year Phase 3 data from ULTIMATE I & II trials showed a low annualized relapse rate of 0.012, with nearly 90% of patients remaining free from disability progression. The treatment demonstrated sustained efficacy and a consistent safety profile, supporting its use in clinical practice. Additional data from ENHANCE and ENABLE...
09-24 13:10
美股大行评级 | Tigress Financial：维持苹果"强烈买入"评级，目标价升至305美元；杰富瑞维持百度"买入"评级，目标价升至157美元
今日重点评级关注：HC Wainwright & Co.：维持Astria Therapeutics"买入"评级，目标价从16美元升至20美元；HC Wainwright & Co.：维持Avalo Therapeutics"买入"评级，目标价从15美元升至25美元
09-18 10:13
B. Riley Securities Maintains Buy on TG Therapeutics, Raises Price Target to $55
B. Riley Securities analyst Mayank Mamtani maintains TG Therapeutics (NASDAQ:TGTX) with a Buy and raises the price target from $53 to $55.
09-18 02:12
TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment
TG Therapeutics announced the start of a Phase 3 trial for subcutaneous BRIUMVI, an anti-CD20 monoclonal antibody, in people with relapsing multiple sclerosis (RMS). Currently approved as an intravenous infusion, BRIUMVI aims to offer a subcutaneous self-administered option for greater flexibility. The trial, designed to assess pharmacokinetics, safety, and efficacy, targets potential approval by 2028, expanding access to approximately 40% of RMS...
09-08 11:30
TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
TG Therapeutics, Inc. announced that its CEO, Michael S. Weiss, will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 8-10, 2025. A fireside chat is scheduled for Monday, September 8, at 10:30am ET, which will be webcast on the company’s website. TG Therapeutics specializes in developing treatments for B-cell diseases and has received FDA approval for BRIUMVI® for treating multiple sclerosis. Fo...
09-04 11:30
TG Therapeutics announces $100M share buyback program
TG Therapeutics (NASDAQ:TGTX) announced on Wednesday that its board authorized a new share repurchase program to buy back shares worth up to $100M from time to time through open-market purchases and o...
09-04 01:40
TG Therapeutic shares are trading higher after the company announced a $100 million repurchase program.
TG Therapeutic shares are trading higher after the company announced a $100 mil...
09-03 23:34
TG Therapeutics files automatic mixed securities shelf
TG Therapeutics (NASDAQ:TGTX) filed automatic mixed securities shelf. Filing More on TG Therapeutics TG Therapeutics: Strong Execution Tempered By An Evolving Market TG Therapeutics falls after Q2 mis...
08-09 05:31
